Variability of clinical characteristic of colorectal cancer patients – analysis of selected parameters Original article
Article Sidebar
Main Article Content
Abstract
Introduction: A steady increase of the incidence of colorectal cancer has been observed for over 30 years, particularly in well-developed countries. Colorectal cancer is one of the lifestyle-related neoplasms and depends on environmental factors.
Aim: Aim of the study was to analyse selected clinical features of colorectal cancer patients.
Material and methods: The study group consisted of 577 consecutive patients with colorectal cancer treated in the Department of Clinical Oncology in Bytom in 2006–2014. The patients were included into the study prospectively. The analysis of selected clinical, pathological and anthropometrical parameters was conducted.
Results: The study group included 237 women and 341 men aged 26 to 86 years (mean age 64.3 ± 9.2 years). Primary tumours were mostly located in the colon and had histological grade 2. The surgical removal of the primary tumour was performed in 540 patients. 65 patients underwent preoperative radiotherapy, 201 – postoperative chemotherapy and 91 – postoperative radio-chemotherapy. 132 of patients obtained the first-line palliative chemotherapy. 88 of patients did not received oncological treatment. KRAS/RAS mutation were determined in 73 patients and the EGFR expression status in 53 patients.
Conclusions: Colorectal cancer patients are a heterogeneous group with differential clinical, pathological and molecular features.
1. Therapeutic management of patients with colorectal cancer largely depends on its location, clinical and pathological stage, patients performance status and comorbidities.
2. Understanding the clinical features of patients with colorectal cancer becomes helpful in designing of screening, which take into account clinical profile of the patient, i.e. age, gender, comorbidities and anthropometric characteristics.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
możliwości leczenia w Polsce. Obywatelskie Porozumienia na Rzecz Onkologii, Warszawa 2014.
2. Didkowska J, Wojciechowska U. Nowotwory złośliwe w Polsce w 2015 roku. Centrum Onkologii, Warszawa 2017.
3. Ferlay J. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014; 136: 359-386.
4. Malvezzi M, Carioli G, Bertuccio P et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol 2018; 29(4): 1016-1022.
5. Brulé SY, Jonker DJ, Karapetis CS et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; 51: 1405-1414.
6. Mesher D, Dove-Edwin I, Sasieni P et al. A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. Int J Cancer 2014; 134: 939-947.
7. Johnson V, Lipton LR, Cummings C et al. Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families. evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families. J Med Gen 2005; 42: 756-762.
8. Austin H, Henley SJ, King J et al. Changes in colorectal cancer incidence rates in young and older adults in the United States. what does it tell us about screening. Cancer Causes Control 2014; 25: 191-201.
9. Singh PN, Fraser GE. Dietary risk factors for colon cancer in a low-risk population. Am J Epidemiol 1998; 148: 761-774.
10. Inra JA, Syngal S. Colorectal cancer in young adults. Dig Dis Sci 2015; 60: 722-733.
11. Bailey CE, Hu CY, You YN et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015; 150: 17-22.
12. Meyer JE, Narang T, Schnoll-Sussman FH et al. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer 2010; 116: 4354-4359.
13. Online: www.esmo.org/Guidelines/Gastrointestinal-Cancers/Early-Colon-Cancer.
14. Online: www.nccn.org/professionals/physician_gls/f_guidelines.asp#colorectal_screening.
15. Kaminski MF, Kraszewska E, Rupinski M et al. Design of the Polish Colonoscopy Screening Program: a randomized health services study. Endoscopy 2015; 47: 1144-1150.
16. Regula J, Rupinski M, Kraszewska E et al. Colonoscopy in colorectal cancer screeening for detection of advanced neoplasia. New Engl J Med 2006; 355: 1863-1872.
17. Online: www.mz.gov.pl/zdrowie-i-profilaktyka/programy-zdrowotne/wykaz-programow/narodowy-program-zwalczania-chorob-nowotworowych.
18. Allemani C, Rachet B, Weir HK et al. Colorectal cancer survival in the USA and Europe: a CONCORD high resolution study. BMJ Open 2013; 3(9): e003055.
19. Schellerer VS, Merkel S, Schumann SC et al. Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer. Int J Colorectal Dis 2012; 27: 71-79.
20. Yusup A, Wang HJ, Rahmutula A et al. Clinical features and prognosis in colorectal cancer patients with different ethnicities in Northwest China. World J Gastroenterol 2013; 19: 7183-7188.
21. Krzakowski M, Warzocha K (ed). Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013. Via Medica, Gdańsk 2013: 179-203.
22. Vincenzi B, Cremolini C, Sartore-Bianchi A et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget 2015; 6: 31604-31612.